The success of the breakthrough therapies program has stakeholders wondering whether some of its tenets could be applied more broadly.
It is a question that likely will come down to FDA's ability to handle the additional work, but given the success of the breakthrough program, there likely will be a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?